WallStSmart
VVOS

Vivos Therapeutics Inc

NASDAQ: VVOS · HEALTHCARE · MEDICAL DEVICES

$0.80
+2.26% today

Updated 2026-04-30

Market cap
$11.46M
P/E ratio
P/S ratio
0.66x
EPS (TTM)
$-2.07
Dividend yield
52W range
$1 – $8
Volume
0.2M

Vivos Therapeutics Inc (VVOS) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
3 of 8
Last 8 quarters
Avg EPS surprise
-20.1%
Last 4 quarters
Revenue YoY growth
+3.4%
Most recent quarter
EPS YoY growth
-107.1%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-6.6%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
-14.2%
2025-11-19
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-26$-0.58-17.2%$1.14$1.15+0.9%
2025-11-19$-0.49-2.1%$2.47$2.12-14.2%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.50$-0.58-17.2%$3.82M+3.4%
2025-09-30$-0.48$-0.49-2.1%$6.78M+75.7%
2025-06-30$-0.39$-0.55-41.0%$3.82M-5.8%
2025-03-31$-0.40$-0.48-20.0%$3.02M-11.8%
2024-12-31$-0.43$-0.28+34.9%$3.70M+13.9%
2024-09-30$-0.61$-0.40+34.4%$3.86M+16.9%
2024-06-30$-1.05$-0.60+42.9%$4.05M+19.4%
2024-03-31$-1.17$-1.63-39.3%$3.42M
2023-12-31$-1.90$-3.05-60.5%$3.25M
2023-09-30$-3.12$-1.62+48.1%$3.30M
2023-06-30$-0.14$-0.18-28.6%$3.40M
2023-03-31$-0.18$-0.07+61.1%

Frequently asked questions

Has Vivos Therapeutics Inc beaten earnings estimates?
Vivos Therapeutics Inc has beaten Wall Street EPS estimates in 3 of its last 8 quarterly reports, with an average EPS surprise of -20.1% over the last 4 quarters.
How does VVOS stock react to earnings?
VVOS stock has moved an average of -6.6% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is Vivos Therapeutics Inc's revenue growth rate?
Vivos Therapeutics Inc reported year-over-year revenue growth of +3.4% in its most recent quarter, with EPS growing -107.1% year-over-year.